Patents have a maximum life of 20 years and, therefore, a 20-year potential monopoly. Patents that are just beginning their life and which have longer to run on the their potential monopoly position understandably will have more value. It is rare that a patent nearing the end of its term will cause a great threat to its competitors. It is almost certain that they will have devised technologies or products of their own by then that will not interfere with the patent owners monopoly position. In addition, one has to take into consideration the potential business life of a patent, i.e., the duration, which a patent is likely to be economically useful, if other subsequent patents are providing better alternatives to it.

A single patent may be worth a billion dollars, another may be completely worthless. How can you discern such differences? With millions of patent documents (both issued patents and applications), there is a lot of information, that if properly leveraged with the correct technologies, can actually help us discern effectively. Benefits of www.ipstreet.com include: (1) All U.S. patent documents from 1976—present (2) [Forthcoming: International patent documents] (3) Unified Search (Boolean Text Search) (4) Concept Search (using Latent Semantics) (5) Meaningful, graphical results (6) Web-based, no installation required (7) Secure transactions and (8) Immediate Access.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

How can you separate "marketing fluff" from a true "value proposition" in this world of TMI (too much information)? This is not an easy question to answer, and we don't claim we have some magic crystal ball. We do, however, believe that our patent search tools are designed in such a way as to provide objective and transparent results to allow you to Discover, Measure, Compare, and Connect business opportunities. Many patent analytics tools are available. So what makes us different? Simple. We take the complexities and reduce them to meaningful visualizations. We take the complex legalese and simplify it to interpretable business intelligence to better understand the analytics of it.

In Nortel's recent bankrupcy, the liquidation of the IP assets led to a bidding war. Google offered $900M for the patents; Apple and Microsoft created an alliance (with RIM, Sony, EMC, Ericsson) to offer $4.5B for the same patents^. Certainly there was a great disparity in these bid prices. How can you objectively determine the value of a portfolio and patent duration. Let the tools at IPstreet.com help you.